Danaher Completes Acquisition Of Nobel Biocare

WASHINGTON, Dec. 11, 2014 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announces that today it will settle the public tender offer for all the registered shares of Nobel Biocare Holding AG ("Nobel Biocare"). The additional acceptance period for the tender offer expired on December 4, 2014.

Danaher now controls approximately 97% of the issued registered shares of Nobel Biocare.

Sometime in the first quarter of 2015, Danaher intends to request the cancellation of the outstanding publicly held registered shares of Nobel Biocare. Alternatively, Danaher may decide to initiate a squeeze-out merger of Nobel Biocare into a company controlled by Danaher. In either such squeeze-out case, Danaher anticipates that the remaining shareholders will receive no more than CHF 17.10 per share (which is the consideration paid in the public tender offer).

Due to the Swiss best price rule that continues to apply during the six months following the end of the additional acceptance period (December 4, 2014) of the public tender offer, Danaher may not pay more than CHF 17.10 per share for any remaining shares of Nobel Biocare purchased in the open market or otherwise.

Furthermore, Danaher intends to have Nobel Biocare apply with SIX Swiss Exchange ("SIX") for the de-listing of the registered shares of Nobel Biocare in accordance with the listing rules of SIX and for an exemption of certain disclosure obligations under the listing rules of SIX until the date of de-listing of the registered shares of Nobel Biocare.

About Danaher

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands have unparalleled leadership positions in some of the most demanding and attractive industries, including health care, environmental and industrial. The company's globally diverse team of 66,000 associates is united by a common culture and operating system, the Danaher Business System. In 2013, Danaher generated $19.1 billion in revenue and its market capitalization exceeded $50 billion. For more information please visit www.danaher.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/danaher-completes-acquisition-of-nobel-biocare-300008334.html

SOURCE Danaher Corporation